Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.

Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, Hodson A, Coats J, Narat S, Morley N, Dyer MJS, Collins GP.

Haematologica. 2019 Feb;104(2):e68-e71. doi: 10.3324/haematol.2018.198812. Epub 2018 Sep 6. No abstract available.

2.

A Case of Fulminant Hepatitis due to Echovirus 9 in a Patient on Maintenance Rituximab Therapy for Follicular Lymphoma.

Morgan C, Thomson SJ, Legg J, Narat S.

Case Rep Hematol. 2015;2015:454890. doi: 10.1155/2015/454890. Epub 2015 May 28.

3.

Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma.

Moore S, Atwal S, Sachchithanantham S, Streetly M, Khan I, Percy L, Narat S, D'Sa S, Rabin N, Johnston R, Schey S, Yong K.

Eur J Haematol. 2013 May;90(5):420-5. doi: 10.1111/ejh.12070. Epub 2013 Mar 14.

PMID:
23294279
4.

The management of peripheral blood cytopenias in systemic lupus erythematosus.

Hepburn AL, Narat S, Mason JC.

Rheumatology (Oxford). 2010 Dec;49(12):2243-54. doi: 10.1093/rheumatology/keq269. Epub 2010 Sep 7. Review.

PMID:
20823093
5.

Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.

O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, Naresh K, Lampert I, Samson D, Narat S, Kanfer E, Olavarria E, Apperley JF, Rahemtulla A.

Bone Marrow Transplant. 2006 Apr;37(8):731-7.

PMID:
16501593
6.

Rituximab in the treatment of refractory autoimmune cytopenias in adults.

Narat S, Gandla J, Hoffbrand AV, Hughes RG, Mehta AB.

Haematologica. 2005 Sep;90(9):1273-4.

7.

Successful treatment of hairy cell leukemia variant with rituximab.

Narat S, Gandla J, Dogan A, Mehta A.

Leuk Lymphoma. 2005 Aug;46(8):1229-32.

PMID:
16085567

Supplemental Content

Support Center